Rinvoq vs Cibinqo

Rinvoq (upadacitinib) and Cibinqo (abrocitinib) are oral JAK inhibitors reviewed for the treatment of atopic dermatitis. Rinvoq is indicated for adults and pediatric patients 12 years of age and older with refractory, moderate-to-severe atopic dermatitis. Its review documents indicate that efficacy versus placebo for co-primary endpoints (IGA 0-1 and EASI-75) was statistically superior. Cibinqo is indicated for moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.

Cibinqo's review documents report an IGA 0 or 1 responder rate of 42.8% for abrocitinib compared to 7.9% for placebo, and an EASI-75 responder rate of 62.7% for abrocitinib compared to 11.8% for placebo. Rinvoq's review also notes a discontinuation rate of 3% in the upadacitinib 15 mg group (M16-045) versus 12% in the placebo group (M16-045).

These drugs were studied in separate trials with different designs, populations, and timepoints. For example, the specific endpoints, patient demographics, and study durations varied between the trials. The figures presented for each drug are from their respective regulatory reviews and are not head-to-head comparisons; therefore, neither drug is presented as superior based on these figures.